News

A proposed interim analysis of the high C-reactive protein (CRP) subgroup showed that ruxolitinib plus regorafenib did not demonstrate a sufficient level of efficacy to warrant continuation. Incyte

The agency granted the treatment priority review with a Prescription Drug User Free Act action date of 23 July 2016. Bezlotoxumab is also under review by the European

The Japan-based company will leverage Medidata’s industry-leading electronic data capture and management technology (Medidata Rave) to evaluate additional indications for OPDIVO, an immunotherapy drug that was initially approved

The Virginia Department of Health (VDH) said the adult resident had recently traveled to a country where Zika virus transmission has been reported. The infection was confirmed through

The company said it will discontinue clinical development of the drug in ulcerative colitis (UC). The Origin phase 2a study demonstrated that GLPG1205 did not differentiate from the

Ofev has been recommended for use within the National Health Service (NHS) in England and Wales in adult patients only if the person has moderate disease with a

The FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of November 16, 2016 . The Marketing Authorisation Application (MAA) for brodalumab in psoriasis was

Encore Vision president and CEO Bill Burns said: "We are pleased to confirm that 75 subjects have been enrolled in the study and to date, there have been

AstraZeneca, GlaxoSmithKline, and Johnson & Johnson Innovation will provide funding and expertise to the collaboration with Imperial College London, the University of Cambridge and University College London (UCL).